Shares of Erytech Pharma SA (NASDAQ:ERYP) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus price objective of $30.00 for the company and are predicting that the company will post ($0.38) EPS for the current quarter, according to Zacks. Zacks has also given Erytech Pharma an industry rank of 55 out of 255 based on the ratings given to its competitors.
Several equities research analysts have recently weighed in on ERYP shares. Zacks Investment Research lowered Erytech Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th. ValuEngine lowered Erytech Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd.
ERYP traded down $0.15 on Thursday, hitting $7.80. 200 shares of the stock traded hands, compared to its average volume of 4,005. Erytech Pharma has a 52 week low of $5.45 and a 52 week high of $21.12. The firm has a market capitalization of $138.32 million, a price-to-earnings ratio of 3.20 and a beta of 1.66. The company has a quick ratio of 7.19, a current ratio of 7.26 and a debt-to-equity ratio of 0.01.
About Erytech Pharma
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Featured Article: What is a Call Option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.